Avenue Therapeutics Files 8-K on Agreements and Acquisitions
Ticker: ATXI · Form: 8-K · Filed: Apr 30, 2025 · CIK: 1644963
Sentiment: neutral
Topics: material-agreement, acquisition, disposition, filing
Related Tickers: AVTX
TL;DR
AVTX filed an 8-K on 4/24/25 covering material agreements, terminations, and asset deals.
AI Summary
On April 24, 2025, Avenue Therapeutics, Inc. filed an 8-K report detailing several material events. These include entering into and terminating a material definitive agreement, and the completion of an acquisition or disposition of assets. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions, including potential changes in asset ownership or strategic partnerships, which could impact the company's future operations and financial standing.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, terminations, and asset dispositions, which can carry inherent risks related to deal structure, regulatory approval, and financial implications.
Key Players & Entities
- Avenue Therapeutics, Inc. (company) — Registrant
- April 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 47-4113275 (ein) — IRS Employer Identification No.
- 1111 Kane Concourse, Suite 301 (address) — Principal Executive Offices
- Bay Harbor Islands, Florida 33154 (address) — Principal Executive Offices
- 781-652-4500 (phone_number) — Registrant's telephone number
FAQ
What specific material definitive agreement did Avenue Therapeutics enter into?
The filing indicates the entry into a material definitive agreement but does not specify its nature in the provided text.
What was the reason for the termination of a material definitive agreement?
The filing states that a material definitive agreement was terminated, but the specific reasons for termination are not detailed in the provided text.
What assets were acquired or disposed of by Avenue Therapeutics?
The filing reports the completion of an acquisition or disposition of assets, but the specific details of the assets involved are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 24, 2025.
What is the principal executive office address for Avenue Therapeutics, Inc.?
The principal executive office address for Avenue Therapeutics, Inc. is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 30, 2025 regarding AVENUE THERAPEUTICS, INC. (ATXI).